Stoke Therapeutics, Inc. STOK Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Stoke Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s free cash flow yield?
- Stoke Therapeutics, Inc. (STOK) reported free cash flow yield of 19.2% in Q1 2025.
- How has Stoke Therapeutics, Inc.'s free cash flow yield changed year-over-year?
- Stoke Therapeutics, Inc.'s free cash flow yield increased by 240.1% year-over-year, from -13.7% to 19.2%.
- What is the long-term trend for Stoke Therapeutics, Inc.'s free cash flow yield?
- Over 4 years (2020 to 2024), Stoke Therapeutics, Inc.'s free cash flow yield has grown at a 67.4% compound annual growth rate (CAGR), from -1.9% to -14.9%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.